News Perspective Therapeutics, Inc.

Stocks

CATX

US46489V3024

Biotechnology & Medical Research

Market Closed - NYSE Other stock markets 00:00:00 18/06/2026 +04			5-day change	1st Jan Change
2.980 ^USD	+1.71%		+1.02%	+8.36%

06-03	Perspective Therapeutics Doses First Meningioma Patient in Phase 1/2a Study Cohort	MT
06-03	Perspective Therapeutics Doses First Patient with [212Pb]Vmt-?-Net in Meningioma Cohort of Phase 1/2A Study	CI

All News

Mentions Relevance

06-03	Perspective Therapeutics Doses First Meningioma Patient in Phase 1/2a Study Cohort	MT
06-03	Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study	AQ
06-03	Perspective Therapeutics Doses First Patient with [212Pb]Vmt-?-Net in Meningioma Cohort of Phase 1/2A Study	CI
05-22	Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma	AQ
05-18	Perspective Therapeutics, Inc. Announces First Patients Dosed In New Cohorts Of Ongoing Phase 1/2a Studies	CI
05-18	Perspective Therapeutics Doses First Patients for New Cohorts of Two Phase 1/2a Studies in Tumors	MT
05-18	Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies	AQ
05-14	Perspective Therapeutics, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-13-2026 02:20 PM
05-12	Perspective Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-12	Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results	AQ
05-10	Perspective Therapeutics, Inc. - Shareholder/Analyst Call
04-24	Perspective Therapeutics to Provide Several Upcoming Corporate Updates	AQ
04-20	Perspective Therapeutics Provides Updated Interim Results From Phase 1/2a Cancer Trial	MT
04-20	Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting	AQ
04-20	Perspective Therapeutics Inc Presents Updated Interim Data of [212Pb]VMT-a-NET in Ongoing Phase 1/2A Clinical Trial	CI
04-02	Perspective Therapeutics to Participate in Upcoming Investor Conferences	AQ
03-23	Perspective Therapeutics, Inc.(NYSEAM:CATX) added to S&P Biotechnology Select Industry Index	CI
03-18	UBS Adjusts Price Target on Perspective Therapeutics to $8 From $7, Maintains Buy Rating	MT
03-18	B. Riley Raises Price Target on Perspective Therapeutics to $13 From $11, Keeps Buy Rating	MT
03-18	Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026	AQ
03-17	RBC Cuts Price Target on Perspective Therapeutics to $14 From $18, Keeps Outperform, Speculative Risk	MT
03-17	Perspective Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-17	Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results	AQ
02-19	Piper Sandler Initiates Coverage on Perspective Therapeutics With Overweight Rating	MT
02-17	Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results	AQ